The Pharmaceutical Post: CDMO strategies for disrupting the biomanufacturing scale-up paradigm
Biopharmaceutical advancements are pivotal in the growth of our market. In the latest edition of The Pharmaceutical Post, Dr Parviz Shamlou SVP, Technical and Scientific Leader at Abzena shares his thoughts on CDMO strategies for biomanufacturing scale-up.
Monoclonal antibodies dominate the biopharmaceutical market. This is due to their highly targeted therapeutic capabilities and broad applicability across a range of diseases. Scale-up and tech-transfer in biomanufacturing are distinctly challenging compared to traditional pharmaceutical manufacturing due to the complexity of biological drugs.
“The translation of these discoveries into commercial products requires scalable manufacturing processes,” says Parviz. “Success often depends on speed-to-market, and the ability to establish scalable manufacturing processes that are cost-effective, efficient and robust.”
With rising costs and smaller budgets, one area where our industry has made strides in fine tuning is in scaling up monoclonal antibodies (mAbs) saving time and money, especially for smaller biotechs. All companies are looking to increase titers and yields and reduce the cost of manufacturing biologics.
The post The Pharmaceutical Post: CDMO strategies for disrupting the biomanufacturing scale-up paradigm appeared first on Abzena.